AIM AIM ImmunoTech Inc. Stock Quote

AIM [AMEX]

Index	-	P/E	-	EPS (ttm)	-0.41	Insider Own	0.60%	Shs Outstand	40.89M	Perf Week	-6.67%
Market Cap	100.90M	Forward P/E	-	EPS next Y	-0.37	Insider Trans	14.38%	Shs Float	40.09M	Perf Month	-12.86%
Income	-14.40M	PEG	-	EPS next Q	-0.09	Inst Own	6.50%	Short Float	3.92%	Perf Quarter	3.96%
Sales	0.20M	P/S	504.52	EPS this Y	82.50%	Inst Trans	13.52%	Short Ratio	0.54	Perf Half Y	-14.29%
Book/sh	1.48	P/B	1.42	EPS next Y	-5.70%	ROA	-26.00%	Target Price	-	Perf Year	-14.98%
Cash/sh	0.81	P/C	2.59	EPS next 5Y	25.00%	ROE	-28.60%	52W Range	1.60 - 4.30	Perf YTD	17.32%
Dividend	-	P/FCF	-	EPS past 5Y	57.90%	ROI	-23.90%	52W High	-51.16%	Beta	-0.81
Dividend %	-	Quick Ratio	36.60	Sales past 5Y	4.20%	Gross Margin	-	52W Low	31.25%	ATR	0.11
Employees	21	Current Ratio	36.60	Sales Q/Q	-16.00%	Oper. Margin	-	RSI (14)	40.02	Volatility	3.60% 5.13%
Optionable	No	Debt/Eq	0.03	EPS Q/Q	19.20%	Profit Margin	-	Rel Volume	0.18	Prev Close	2.11
Shortable	Yes	LT Debt/Eq	0.03	Earnings	-	Payout	-	Avg Volume	2.92M	Price	2.10
Recom	2.00	SMA20	-7.73%	SMA50	-10.50%	SMA200	-6.89%	Volume	522,174	Change	-0.47%

Apr-07-21 09:15AM	AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases GlobeNewswire
Mar-31-21 09:15AM	AIM ImmunoTech Reports 2020 Year-End Financial Results GlobeNewswire +6.07%
Mar-22-21 08:45AM	AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Centers Ongoing Study in Cancer Patients with COVID-19 GlobeNewswire
Mar-11-21 07:00AM	AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th GlobeNewswire
Mar-10-21 06:55AM	AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference GlobeNewswire
Mar-08-21 09:15AM	AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study GlobeNewswire
Mar-04-21 06:50AM	AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th GlobeNewswire -7.52%
Feb-24-21 09:15AM	AIM ImmunoTechs Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer GlobeNewswire
Feb-16-21 09:15AM	AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy GlobeNewswire
Feb-10-21 09:15AM	AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands GlobeNewswire +8.05%
Feb-05-21 06:50AM	AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials GlobeNewswire -10.91%
Jan-29-21 06:55AM	AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen GlobeNewswire
Jan-15-21 06:45AM	AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET GlobeNewswire
Jan-11-21 06:45AM	AIM ImmunoTech Postpones Investor Conference Call. Will Reschedule for a Later Date GlobeNewswire
Jan-06-21 06:45AM	AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue Long Hauler Patient Dosed with Ampligen GlobeNewswire
Dec-24-20 09:05AM	AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers GlobeNewswire +5.08%
07:52AM	AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers ACCESSWIRE
Dec-21-20 09:40AM	AIM ImmunoTech Inc.s Drug Ampligen Awarded FDAs Orphan Drug Designation Status for the Treatment of Pancreatic Cancer GlobeNewswire +14.14%
06:45AM	AIM ImmunoTech Inc.s Drug Ampligen Awarded FDAs Orphan Drug Designation Status for the Treatment of Pancreatic Cancer GlobeNewswire
Nov-25-20 06:45AM	AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19 GlobeNewswire +5.95%
Nov-15-20 07:01AM	AIM ImmunoTech Inc. (NYSEMKT:AIM) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St.
07:00AM	What Can We Learn About AIM ImmunoTech's (NYSEMKT:AIM) CEO Compensation? Simply Wall St.
Nov-13-20 07:30AM	AIM ImmunoTech Provides Third Quarter 2020 Business Update GlobeNewswire +7.41%
Nov-02-20 09:00AM	AIM ImmunoTech Announces PLOS ONEs Publication of New Data Analyses Showing Importance of Disease Duration on Ampligens Positive Role in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) GlobeNewswire
Oct-30-20 10:00AM	BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year GlobeNewswire
Oct-22-20 07:30AM	AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th GlobeNewswire
Oct-06-20 09:00AM	AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 Long Haulers in the AMP-511 ME/CFS Clinical Trial of Ampligen GlobeNewswire
Sep-22-20 06:50AM	AIM ImmunoTech Receives Statistically Significant Positive Survival Results in Pancreatic Cancer from Erasmus University Medical Center, Rotterdam, Netherlands ACCESSWIRE +24.51%
Sep-16-20 06:50AM	AIM ImmunoTech Highlights Start of Recruitment in Roswell Park Clinical Trial Incorporating Ampligen in the Treatment of Cancer Patients with Mild or Moderate COVID-19 ACCESSWIRE
Sep-10-20 06:50AM	AIM ImmunoTech to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14th ACCESSWIRE
Sep-08-20 06:50AM	AIM ImmunoTech CEO to Participate in Virtual Panel: 'New Approaches to COVID-19: Hidden Breakthroughs,' on Thursday, September 10th ACCESSWIRE +7.34%
Aug-31-20 05:00PM	LD Micro - 360 Companies Set to Present this Week ACCESSWIRE -5.86%
Aug-27-20 09:15AM	AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious Viral Yields by 90% Using New In Vitro Model; Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19 ACCESSWIRE +14.62%
Aug-25-20 06:55AM	AIM ImmunoTech to Present at The LD 500 Virtual Conference on September 1st ACCESSWIRE
Aug-21-20 11:18AM	Insider Buys AIM ImmunoTech's Shares Benzinga
Aug-17-20 09:18AM	We're Hopeful That AIM ImmunoTech (NYSEMKT:AIM) Will Use Its Cash Wisely Simply Wall St.
06:55AM	AIM ImmunoTech Provides Second Quarter 2020 Business Update and Reports Progress in Both COVID-19 and Cancer Trials ACCESSWIRE
Aug-05-20 09:00AM	LD Micro Announces Preliminary List of Presenters for the LD 500 ACCESSWIRE +5.02%
Aug-03-20 08:00AM	49 Public Companies to Present at the SNN Network Virtual Conference on August 3-6, 2020 ACCESSWIRE
Jul-27-20 06:55AM	AIM ImmunoTech to Present at the SNN Network Virtual Investor Conference on Monday, August 3rd ACCESSWIRE
Jul-09-20 06:30AM	AIM ImmunoTech Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center Supporting Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19 Patients with Cancer ACCESSWIRE
Jul-06-20 09:00AM	AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as Potential Vaccine Adjuvant for COVID-19 ACCESSWIRE
Jun-29-20 06:55AM	AIM ImmunoTech Added to Russell Microcap(R) Index ACCESSWIRE -5.54%
Jun-15-20 08:00AM	AIM ImmunoTech Provides Update on Commercial Launch of Ampligen(R) in Argentina for the Treatment of Chronic Fatigue Syndrome ACCESSWIRE
Jun-11-20 09:05AM	AIM ImmunoTech Files Provisional Patent Application for the Use of Ampligen(R) as a Potential Therapy for COVID-19 Induced Chronic Fatigue ACCESSWIRE -7.17%
May-14-20 06:50AM	AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer; Provides Corporate Business Update for the First Quarter of 2020 ACCESSWIRE +25.11%
Apr-29-20 06:30AM	AIM ImmunoTechs CEO to Present at Maxims Infectious Disease Virtual Conference ACCESSWIRE
Apr-20-20 06:30AM	AIM ImmunoTechs CEO to Present at the Planet Microcap Showcase Virtual Investor Conference 2020 ACCESSWIRE
Apr-06-20 06:30PM	AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic ACCESSWIRE
01:00PM	AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic ACCESSWIRE
06:30AM	AIM ImmunoTech Announces the National Cancer Institutes Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers ACCESSWIRE
Mar-31-20 06:45AM	AIM ImmunoTech Reports 2019 Year-end Financial Results ACCESSWIRE
Mar-26-20 08:00AM	AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic ACCESSWIRE +10.22%
Mar-09-20 06:30AM	AIM ImmunoTechs Drug Ampligen to Be Tested by Japans National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19 ACCESSWIRE +190.48%
Mar-08-20 11:34AM	Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April MarketWatch
Feb-27-20 06:30AM	AIM ImmunoTech Joins with ChinaGoAbroad for an Ampligen China Entry Against COVID-19, the New SARS-like Coronavirus Disease Epidemic ACCESSWIRE +42.50%
Feb-18-20 06:30AM	AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic ACCESSWIRE
Feb-12-20 06:30AM	AIM ImmunoTechs CEO to Appear Live Today on FOX Business Networks The Claman Countdown and Cheddars Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus ACCESSWIRE +17.92%
Feb-11-20 06:30AM	AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen® for Use Against the SARS-like Wuhan 2019 Novel Coronavirus GlobeNewswire +28.48%
06:30AM	AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus ACCESSWIRE
Feb-05-20 06:30AM	AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies ACCESSWIRE
Jan-16-20 05:27AM	Read This Before Selling AIM ImmunoTech Inc. (NYSEMKT:AIM) Shares Simply Wall St.
Dec-11-19 12:20PM	AIM ImmunoTech to Present at the Investor Summit in Philadelphia ACCESSWIRE
06:30AM	AIM ImmunoTech to Present at the Investor Summit in Philadelphia ACCESSWIRE
Dec-04-19 06:30AM	AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020 ACCESSWIRE -7.95%
Nov-15-19 10:25AM	CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019 ACCESSWIRE
06:30AM	AIM ImmunoTech Provides Business Update for the Third Quarter of 2019 ACCESSWIRE
Oct-23-19 06:30AM	AIM ImmunoTech to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference ACCESSWIRE
Oct-07-19 06:30AM	AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified ACCESSWIRE +7.23%
Sep-25-19 09:50AM	AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering ACCESSWIRE -43.37%
Sep-24-19 06:30AM	AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center ACCESSWIRE -14.53%
06:00AM	AIM ImmunoTechs Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome ACCESSWIRE
Sep-19-19 08:43AM	AIM ImmunoTech Shares Spike Up 90% After $6.42M 'Breakthrough Award' Benzinga +32.91%
06:50AM	AIM ImmunoTech Inc. Announces the U.S. Department of Defenses Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer ACCESSWIRE
Sep-16-19 06:50AM	AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer ACCESSWIRE
Sep-13-19 06:50AM	AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City ACCESSWIRE
Sep-10-19 07:30AM	AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center ACCESSWIRE
Sep-09-19 07:45AM	AIM ImmunoTech Inc. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol 'AIM' ACCESSWIRE
Sep-06-19 06:30AM	AIM ImmunoTech to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 10th ACCESSWIRE

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
APPELROUTH STEWART	Director	Feb 25	Buy	2.35	10,638	24,999	92,538	Feb 25 03:07 PM
EQUELS THOMAS K.	CEO & President	Feb 24	Buy	2.26	11,062	25,000	209,630	Feb 24 12:03 PM
EQUELS THOMAS K.	CEO	Dec 17	Buy	1.72	14,535	25,000	198,568	Dec 17 12:22 PM
EQUELS THOMAS K.	CEO & President	Sep 03	Buy	2.03	12,316	25,001	184,033	Sep 03 10:53 AM
EQUELS THOMAS K.	CEO	Aug 21	Buy	2.33	10,730	25,001	171,717	Aug 21 08:08 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience